$TMCI
TREACE MEDICAL CONCEPTS, INC. Stock $tmci

$tmci Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000095017024054480 Filed on May 07, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$44.46M	$51.11M
YoY Change	5.96%	21.12%
Cost Of Revenue	$8.781M	$10.13M
YoY Change	14.41%	25.97%
Gross Profit	$35.67M	$40.98M
YoY Change	4.07%	19.98%
Gross Profit Margin	80.25%	80.19%
Selling, General & Admin	$51.90M	$54.69M
YoY Change	18.48%	22.84%
% of Gross Profit	145.48%	133.45%
Research & Development	$5.157M	$5.259M
YoY Change	46.26%	54.13%
% of Gross Profit	14.46%	12.83%
Depreciation & Amortization	$2.116M	$1.909M
YoY Change	92.36%	112.11%
% of Gross Profit	5.93%	4.66%
Operating Expenses	$57.06M	$59.95M
YoY Change	20.55%	25.07%
Operating Profit	-$21.38M	-$18.97M
YoY Change	63.82%	37.69%
Interest Expense	$1.312M	$1.317M
YoY Change	2.34%	2.49%
% of Operating Profit
Other Income/Expense, Net	$176.0K	$292.0K
YoY Change	-77.46%	-9.32%
Pretax Income	-$21.21M	-$18.68M
YoY Change	72.81%	38.81%
Income Tax
% Of Pretax Income
Net Earnings	-$21.21M	-$18.68M
YoY Change	72.81%	38.81%
Net Earnings / Revenue	-47.7%	-36.54%
Basic Earnings Per Share	-$0.34	-$0.30
Diluted Earnings Per Share	-$0.34	-$0.30
COMMON SHARES
Basic Shares Outstanding	62.01M	61.76M
Diluted Shares Outstanding	62.08M	61.79M

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$95.05M	$110.0M
YoY Change	-31.86%	-35.54%
Cash & Equivalents	$18.18M	$9.334M
Short-Term Investments	$76.87M	$100.7M
Other Short-Term Assets	$9.668M	$11.45M
YoY Change	82.97%	149.57%
Inventory	$41.28M	$35.86M
Prepaid Expenses
Receivables	$25.56M	$30.08M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$171.6M	$187.4M
YoY Change	-13.4%	-16.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.25M	$24.52M
YoY Change	24.75%	54.05%
Goodwill	$12.82M	$12.82M
YoY Change	0.0%
Intangibles	$8.550M	$8.787M
YoY Change	-10.0%
Long-Term Investments
YoY Change
Other Assets	$146.0K	$146.0K
YoY Change	0.0%	-32.09%
Total Long-Term Assets	$54.53M	$55.33M
YoY Change	5.79%	112.5%
TOTAL ASSETS
Total Short-Term Assets	$171.6M	$187.4M
Total Long-Term Assets	$54.53M	$55.33M
Total Assets	$226.1M	$242.7M
YoY Change	-9.44%	-2.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.07M	$21.15M
YoY Change	121.86%	316.65%
Accrued Expenses	$13.73M	$15.16M
YoY Change	94.15%	90.13%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$44.45M	$47.05M
YoY Change	48.04%	101.96%
LONG-TERM LIABILITIES
Long-Term Debt	$53.16M	$53.08M
YoY Change	0.56%	0.56%
Other Long-Term Liabilities	$37.00K	$37.00K
YoY Change	0.0%	48.0%
Total Long-Term Liabilities	$53.19M	$53.12M
YoY Change	0.56%	0.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.45M	$47.05M
Total Long-Term Liabilities	$53.19M	$53.12M
Total Liabilities	$113.9M	$116.3M
YoY Change	14.3%	27.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$174.1M	-$152.9M
YoY Change	57.73%	55.73%
Common Stock	$62.00K	$62.00K
YoY Change	0.0%	1.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$250.0K	$250.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	$112.1M	$126.4M
YoY Change
Total Liabilities & Shareholders Equity	$226.1M	$242.7M
YoY Change	-9.44%	-2.59%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$21.21M	-$18.68M
YoY Change	72.81%	38.81%
Depreciation, Depletion And Amortization	$2.116M	$1.909M
YoY Change	92.36%	112.11%
Cash From Operating Activities	-$13.90M	-$7.221M
YoY Change	66.73%	-58.26%
INVESTING ACTIVITIES
Capital Expenditures	$1.729M	$3.927M
YoY Change	-59.13%	165.7%
Acquisitions
YoY Change
Other Investing Activities	$24.16M	$7.685M
YoY Change	-490.21%	-109.73%
Cash From Investing Activities	$22.43M	$3.758M
YoY Change	-315.23%	-104.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	311.0K	-185.0K
YoY Change	-73.64%	-100.17%
NET CHANGE
Cash From Operating Activities	-13.90M	-7.221M
Cash From Investing Activities	22.43M	3.758M
Cash From Financing Activities	311.0K	-185.0K
Net Change In Cash	8.847M	-3.648M
YoY Change	-150.33%	-135.98%
FREE CASH FLOW
Cash From Operating Activities	-$13.90M	-$7.221M
Capital Expenditures	$1.729M	$3.927M
Free Cash Flow	-$15.63M	-$11.15M
YoY Change	24.35%	-40.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001630627
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.treace.com/20240331#OperatingLeaseAndOtherLiabilities
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.treace.com/20240331#OperatingLeaseAndOtherLiabilities
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-40355
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	Treace Medical Concepts, Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1052611
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Palmetto Park Place
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Ponte Vedra
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32081
CY2024Q1	dei	City Area Code CityAreaCode	904
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	373-5940
CY2024Q1	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2024Q1	dei	Trading Symbol TradingSymbol	TMCI
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	62008135
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9334000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12982000
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	100672000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	110216000
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1076000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	980000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30083000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	38063000
CY2024Q1	us-gaap	Inventory Net InventoryNet	35860000
CY2023Q4	us-gaap	Inventory Net InventoryNet	29245000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11448000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7853000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	187397000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	198359000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24517000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22298000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	713000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	475000
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8787000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9025000
CY2024Q1	us-gaap	Goodwill Goodwill	12815000
CY2023Q4	us-gaap	Goodwill Goodwill	12815000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9064000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9264000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	146000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	146000
CY2024Q1	us-gaap	Assets Assets	242726000
CY2023Q4	us-gaap	Assets Assets	251907000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	21149000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11835000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15155000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10458000
CY2024Q1	tmci	Accrued Commissions AccruedCommissions	5527000
CY2023Q4	tmci	Accrued Commissions AccruedCommissions	10759000
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4196000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7549000
CY2024Q1	tmci	Operating Lease And Other Liabilities OperatingLeaseAndOtherLiabilities	1022000
CY2023Q4	tmci	Operating Lease And Other Liabilities OperatingLeaseAndOtherLiabilities	4432000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	47049000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45033000
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	917000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	992000
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	53083000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	53008000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16166000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15891000
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37000
CY2024Q1	us-gaap	Liabilities Liabilities	116335000
CY2023Q4	us-gaap	Liabilities Liabilities	113969000
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	47932000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18968000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13776000
CY2024Q1	us-gaap	Investment Income Net InvestmentIncomeNet	1535000
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	1479000
CY2024Q1	us-gaap	Interest Expense InterestExpense	1317000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61948776
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61749654
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61929172
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61749654
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	62000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	62000
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	279433000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	271973000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152923000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-134247000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	69000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	163000
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	19604
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1218
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	250000
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	13000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	126391000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	137938000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	242726000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	251907000
CY2024Q1	us-gaap	Revenues Revenues	51108000
CY2023Q1	us-gaap	Revenues Revenues	42195000
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10127000
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8039000
CY2024Q1	us-gaap	Gross Profit GrossProfit	40981000
CY2023Q1	us-gaap	Gross Profit GrossProfit	34156000
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	40328000
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	33655000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5259000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3412000
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14362000
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10865000
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	59949000
CY2023Q1	us-gaap	Interest Expense InterestExpense	1285000
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	74000
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	128000
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	292000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	322000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18676000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13454000
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-94000
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-29000
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18770000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13483000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.3
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.3
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61792788
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61792788
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58723760
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58723760
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	137938000
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	52000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	7408000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18676000
CY2024Q1	tmci	Unrealized Loss On Available For Sale Marketable Securities UnrealizedLossOnAvailableForSaleMarketableSecurities	94000
CY2024Q1	tmci	Shares Directly Withheld From Employees For Tax Payment SharesDirectlyWithheldFromEmployeesForTaxPayment	-237000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	126391000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	60529000
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	352000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2692000
CY2023Q1	tmci	Issuance Cost And Underwriting Discount IssuanceCostAndUnderwritingDiscount	7500000
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	107527000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13454000
CY2023Q1	tmci	Unrealized Loss On Available For Sale Marketable Securities UnrealizedLossOnAvailableForSaleMarketableSecurities	29000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	157617000
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-18676000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-13454000
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1909000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	924000
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	159000
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	38000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7408000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2692000
CY2024Q1	tmci	Non Cash Lease Expense NonCashLeaseExpense	592000
CY2023Q1	tmci	Non Cash Lease Expense NonCashLeaseExpense	626000
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	75000
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	74000
CY2024Q1	tmci	Recovery Of Loss Reserve For Surgical Instruments RecoveryOfLossReserveForSurgicalInstruments	0
CY2023Q1	tmci	Recovery Of Loss Reserve For Surgical Instruments RecoveryOfLossReserveForSurgicalInstruments	23000
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	335000
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	297000
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-90000
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-0
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7821000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3793000
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6615000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3189000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1495000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	963000
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-69000
CY2024Q1	tmci	Payable To Broker For Unsettled Marketable Security Purchases PayableToBrokerForUnsettledMarketableSecurityPurchases	0
CY2023Q1	tmci	Payable To Broker For Unsettled Marketable Security Purchases PayableToBrokerForUnsettledMarketableSecurityPurchases	710000
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-657000
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-478000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9314000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3592000
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6918000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4076000
CY2024Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-107000
CY2023Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-25000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7221000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17259000
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	28711000
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	99550000
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	36396000
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	20548000
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3927000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1478000
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3758000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-80480000
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	7500000
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	10600000
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	107527000
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	52000
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	352000
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	237000
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-185000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	107879000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3648000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10140000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12982000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19473000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9334000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29613000
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1317000
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1285000
CY2024Q1	tmci	Right Of Use Asset Obtained In Exchange For Operating Lease Incentive RightOfUseAssetObtainedInExchangeForOperatingLeaseIncentive	-0
CY2023Q1	tmci	Right Of Use Asset Obtained In Exchange For Operating Lease Incentive RightOfUseAssetObtainedInExchangeForOperatingLeaseIncentive	35000
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-94000
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-29000
CY2024Q1	tmci	Unsettled Matured Marketable Security Receivable From Broker UnsettledMaturedMarketableSecurityReceivableFromBroker	2100000
CY2023Q1	tmci	Unsettled Matured Marketable Security Receivable From Broker UnsettledMaturedMarketableSecurityReceivableFromBroker	0
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Formation and Business of the Company</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Company</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treace Medical Concepts, LLC was formed on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 29, 2013</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as a Florida limited liability company. Effective July 1, 2014, the entity converted to a Delaware corporation and changed its name to Treace Medical Concepts, Inc. (the "Company"). The Company is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. The Company received 510(k) clearance for the Lapiplasty System in March 2015 and began selling its surgical medical devices in September 2015. The Company has pioneered the proprietary Lapiplasty 3D Bunion Correction System – a combination of instruments, implants and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. In addition, the Company offers advanced instrumentation and implants for use in other procedures performed in high frequency with bunion surgery. The Company operates from its corporate headquarters located in Ponte Vedra, Florida.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Public Offering and Follow-on Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 27, 2021, the Company completed its initial public offering ("IPO"). The Company received net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">107.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the IPO. O</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n February 10, 2023, the Company completed a follow-on offering that resulted in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">107.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquisition of RedPoint Medical3D</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 12, 2023 (the "closing date"), the Company acquired certain assets of MIOS Marketing, LLC d/b/a RedPoint Medical3D ("RPM-3D"), a medical technology company offering pre-operative planning and patient-specific guides designed to deliver accurate surgical correction of deformities tailored to the patient's unique foot anatomy. RPM-3D's 22 patent applications further expand and reinforce the Company's global intellectual property portfolio covering technologies for the correction of bunion and related deformities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in exchange for certain assets used in providing pre-operative planning and patient-specific guides for the surgical correction of foot and ankle deformities and agreed to make additional payments upon completion of certain milestones. The original terms are as follows: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon completion of certain transition services at 12 months from the closing date, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon completion of certain technological advancements milestone within 12 months of the closing date, and, subject to prior completion of the transition services and the technological advancements milestone, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the issuance of certain patent claims. Payments made for the transition services and patent claims require satisfaction of such milestones, as well as the continued service of key individuals.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the first quarter of 2024, the Company and RPM-3D evaluated the status of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> milestones and amended the original terms associated with the milestone payments. The maximum amount to be paid upon the achievement of the milestone payments has been reduced from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and is subject to successful completion of the transition services milestone at the first anniversary date of the acquisition. Upon successful completion of the transition services milestone, the payments are scheduled as follows: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on July 15, 2024 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on January 15, 2025. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> milestone payments would be made if the transition services milestone is not achieved by the acquisition anniversary date.</span></p>
CY2024Q1	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2013-07-29
CY2024Q1	tmci	Number Of Milestones NumberOfMilestones	3
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant estimates and assumptions include valuation of intangible assets and goodwill, reserves and write-downs related to accounts receivable, inventories, the recoverability of long-term assets, deferred tax assets and related valuation allowances, contingencies, and stock-based compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued contingent liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2024Q1	tmci	Accrued Contingent Liabilities AccruedContingentLiabilities	0
CY2023Q4	tmci	Accrued Contingent Liabilities AccruedContingentLiabilities	0
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation ("FDIC") insured limits. The Company's available-for-sale securities portfolio primarily consists of U.S. treasury and agency securities, money market funds, commercial paper, Yankee CDs, high credit quality asset-backed securities and corporate debt securities. The Company's investment policy requires its available-for-sale securities to meet certain criteria including investment type, credit ratings, and a maximum portfolio duration of one year. If any of the financial institutions where the Company holds deposits were to fail or be taken over by the FDIC, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">its access to these accounts could be temporarily unavailable or permanently lost for the amounts in excess of the FDIC insured limits. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have material cash deposits in excess of the FDIC insured limits at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company earns revenue from the sale of its products to customers such as hospitals and ambulatory surgery centers. The Company’s accounts receivable is derived from revenue earned from customers. On March 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, no customer accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of accounts receivable. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were no customers that represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of revenue.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable as of March 31, 2024 includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, prior to an allowance for credit losses, due from a customer that has filed for bankruptcy in May 2024. The Company is assessing the impact of the bankruptcy filing related to this accounts receivable and its relationship with this customer. While the Company maintains an allowance for doubtful accounts, there can be no assurance that this receivable will be timely collected, if at all, or that the current allowance for doubtful accounts will be adequate to offset the credit risk related to this matter, and no assurance that the Company will have an ongoing relationship with this customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0
CY2024Q1	tmci	Accounts Receivable Prior To An Allowance For Credit Losses AccountsReceivablePriorToAnAllowanceForCreditLosses	2000000
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	0
CY2024Q1	us-gaap	Cash Cash	4772000
CY2023Q4	us-gaap	Cash Cash	9822000
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9334000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12982000
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	100603000
CY2024Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	131000
CY2024Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	62000
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	100672000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	110053000
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	196000
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	33000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	110216000
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	34936000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	31046000
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10419000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8748000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24517000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22298000
CY2024Q1	tmci	Depreciation And Amortization Expense On Physical Assets And Software DepreciationAndAmortizationExpenseOnPhysicalAssetsAndSoftware	1700000
CY2023Q1	tmci	Depreciation And Amortization Expense On Physical Assets And Software DepreciationAndAmortizationExpenseOnPhysicalAssetsAndSoftware	900000
CY2024Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2024Q1	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	1860000
CY2023Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	2305000
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	425000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	417000
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	774000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	424000
CY2024Q1	tmci	Accrued Compensation Expense AccruedCompensationExpense	7602000
CY2023Q4	tmci	Accrued Compensation Expense AccruedCompensationExpense	3340000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4494000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3972000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15155000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10458000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	864000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1404000
CY2024Q1	tmci	Contingent Consideration ContingentConsideration	0
CY2023Q4	tmci	Contingent Consideration ContingentConsideration	2977000
CY2024Q1	us-gaap	Other Liabilities OtherLiabilities	158000
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	51000
CY2024Q1	tmci	Operating Lease And Other Liabilities OperatingLeaseAndOtherLiabilities	1022000
CY2023Q4	tmci	Operating Lease And Other Liabilities OperatingLeaseAndOtherLiabilities	4432000
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	54000000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	54000000
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	917000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	992000
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	53083000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	53008000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	33333000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	20667000
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	54000000
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	917000
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	53083000
CY2022Q2	us-gaap	Line Of Credit Facility Borrowing Capacity Description LineOfCreditFacilityBorrowingCapacityDescription	The Company is required to either (i) maintain a minimum drawn balance under the revolving loan facility or (ii) pay a minimum balance fee that is equal to the amount of the minimum balance deficit multiplied by the applicable interest rate during the period. If the outstanding balance under the revolving loan facility exceeds the lesser of (i) 50% of the revolving borrowing capacity or (ii) 50% of the borrowing base, or the Company is in default, MidCap will apply funds collected from the Company's lockbox account to reduce the outstanding balance of the revolving loan facility ("Lockbox Deductions").
CY2022Q2	tmci	Revolving Borrowing Capacity Percentage RevolvingBorrowingCapacityPercentage	0.50
CY2022Q2	us-gaap	Line Of Credit Facility Interest Rate Description LineOfCreditFacilityInterestRateDescription	The loans bear interest at an annual rate based on a 30-day forward looking secured overnight financing rate plus 0.10% (subject to a floor of 1.0% and a cap of 3.0% for both loan agreements) plus (i) 6.0% under the term loan agreement and (ii) 4.0% under the revolving loan facility.
CY2022Q2	us-gaap	Line Of Credit Facility Frequency Of Payments LineOfCreditFacilityFrequencyOfPayments	Interest is payable monthly in arrears on the first day of each month and on the maturity of the loan agreements. The term loan and the revolving loan facility are accruing interest as of March 31, 2024 at the capped interest rates of 9% and 7%, respectively. The Company is obligated to pay interest only for the first 48 months and straight-line amortization for the remaining 12 months, subject to the Company’s election to extend the initial interest-only period by 12 months to 60 months total if the Company’s trailing twelve-month revenue is at or above certain levels.
CY2022Q2	tmci	Debt Instrument Repayment Fee Percentage Year1 DebtInstrumentRepaymentFeePercentageYear1	0.03
CY2022Q2	tmci	Debt Instrument Repayment Fee Percentage Year3 DebtInstrumentRepaymentFeePercentageYear3	0.01
CY2022Q2	tmci	Debt Instrument Repayment Fee Percentage Final DebtInstrumentRepaymentFeePercentageFinal	0.03
CY2024Q1	tmci	Accrued Contingent Liabilities AccruedContingentLiabilities	0
CY2023Q4	tmci	Accrued Contingent Liabilities AccruedContingentLiabilities	0
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7408000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2692000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18676000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13454000
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61792788
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61792788
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58723760
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58723760
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.3
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.3
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11402377
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8804111

Files In Submission

Name	View Source	Status
0000950170-24-054480-index-headers.html	Edgar Link	pending
0000950170-24-054480-index.html	Edgar Link	pending
0000950170-24-054480.txt	Edgar Link	pending
0000950170-24-054480-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tmci-20240331.htm	Edgar Link	pending
tmci-20240331.xsd	Edgar Link	pending
tmci-ex31_1.htm	Edgar Link	pending
tmci-ex31_2.htm	Edgar Link	pending
tmci-ex32_1.htm	Edgar Link	pending
tmci-ex32_2.htm	Edgar Link	pending
tmci-20240331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TMCI
TREACE MEDICAL CONCEPTS, INC. Stock $tmci

2024 Q2 Form 10-Q Financial Statement

#000095017024054480 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TMCI TREACE MEDICAL CONCEPTS, INC. Stock $tmci

2024 Q2 Form 10-Q Financial Statement

#000095017024054480 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TMCI
TREACE MEDICAL CONCEPTS, INC. Stock $tmci